List of publications using LY 2157299 (Axon 1491) purchased from Axon Medchem
(total 20 publications; updated on AUGUST-2017)
Keratin 19, a cancer stem cell marker in human hepatocellular carcinoma.
Kawai, T., Yasuchika, K., Ishii, T., Katayama, H., Yoshitoshi, E. Y., Ogiso, S., ... & Uemoto, S. (2015).
Clin Cancer Res. 2015 Mar 27. [Epub ahead of print]
A Novel Preclinical Method to Quantitatively Evaluate Early-Stage Metastatic Events at the Murine Blood–Brain Barrier.
Adkins, C. E., Nounou, M. I., Mittapalli, R. K., Terrell-Hall, T. B., Mohammad, A. S., Jagannathan, R., & Lockman, P. R. (2015).
Cancer Prev Res (Phila). 2015 Jan;8(1):68-76.
COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OSTEOARTHRITIS.
Cao, Xu.
U.S. Patent No. 20,150,139,909. 21 May 2015.
2014
Benzalkonium Chloride Induces Subconjunctival Fibrosis Through the COX-2–Modulated Activation of a TGF-β1/Smad3 Signaling Pathway.
Huang, C., Wang, H., Pan, J., Zhou, D., Chen, W., Li, W., ... & Liu, Z. (2014).
Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):8111-22.
Protease‐activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model.
Shi, K., Queiroz, K., Roelofs, J. J., van Noesel, C. J., Richel, D. J., & Spek, C. A. (2014).
J Pathol. 2014 Nov;234(3):398-409.
Targeted Therapy Sensitivity and Resistance in Solid Malignancies.
Jokinen, E. (2014).
PhD thesis. University of Oulu.
*LY2157299, SD208, XAV939 and DBZ from Axon Medchem have been used in this study.
2013
Programmed cell senescence during mammalian embryonic development.
Muñoz-Espín, D., Cañamero, M., Maraver, A., Gómez-López, G., Contreras, J., Murillo-Cuesta, S., ... & Serrano, M. (2013).
Cell. 2013 Nov 21;155(5):1104-18.
*LY2157299 from Axon Medchem has been used in this study.
Glucocorticoids alleviate intestinal ER stress by enhancing protein folding and degradation of misfolded proteins.
Das, I., Png, C. W., Oancea, I., Hasnain, S. Z., Lourie, R., Proctor, M., ... & McGuckin, M. A. (2013).
J Exp Med. 2013 Jun 3;210(6):1201-16.
2012 and earlier
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Lemke, D., Pfenning, P. N., Sahm, F., Klein, A. C., Kempf, T., Warnken, U., ... & Wick, W. (2012).
Clinical Cancer Research, 18(1), 105-117.
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Lemke, D., Pfenning, P. N., Sahm, F., Klein, A. C., Kempf, T., Warnken, U., ... & Wick, W. (2012).
Clin Cancer Res. 2012 Jan 1;18(1):105-17.
Cardiac treatment using anti-fibrotic agents.
Dudley, S. C., & Sutliff, R. L. (2011).
U.S. Patent Application 13/091,972. US 20110262398 A1.
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.
Lonardo, E., Hermann, P. C., Mueller, M. T., Huber, S., Balic, A., Miranda-Lorenzo, I., ... & Heeschen, C. (2011).
Cell Stem Cell, 9(5), 433-446.
(This is an incomplete list, updated in AUGUST-2017)
